Medscape is available in 5 Language Editions – Choose your Edition here.


Subacute Cutaneous Lupus Erythematosus (SCLE)

  • Author: Janice Lin, MD, MPH; Chief Editor: William D James, MD  more...
Updated: Mar 07, 2016


Subacute cutaneous lupus erythematosus (SCLE) is a nonscarring, non–atrophy-producing, photosensitive dermatosis. SCLE commonly develops in sun-exposed areas, including the upper back, shoulders, extensor arms, neck, and upper torso, while the face is often spared. These skin lesions can appear as either papulosquamous (psoriasiform) or annular lesions.

SCLE is a subtype of cutaneous lupus erythematosus (CLE); other subtypes include acute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus. Chronic cutaneous lupus erythematosus includes discoid lupus erythematosus, lupus erythematous panniculitis/profundus, lupus tumidus, and chilblain lupus.

SCLE may occur in patients with systemic lupus erythematosus (SLE), Sjögren syndrome, or deficiency of the second component of complement (C2d), or it may be drug-induced. SCLE is the most common subtype of CLE associated with Sjögren syndrome.[1] Some patients with SCLE may also have acute cutaneous lupus erythematosus (ACLE), if they have concomitant SLE, or the lesions of discoid lupus erythematosus (DLE), and some may develop small-vessel vasculitis. (See the image below.)

Early lesions of subacute cutaneous lupus erythema Early lesions of subacute cutaneous lupus erythematosus may simulate polymorphous light eruption.

See Cutaneous Clues to Accurately Diagnosing Rheumatologic Disease, a Critical Images slideshow, to help recognize cutaneous manifestations of rheumatologic diseases.

Patients with SCLE frequently fulfill 4 or more of the criteria used to classify SLE. Serologic abnormalities are common. Therapy with sunscreens, topical corticosteroids, and antimalarial agents is often effective; however, some patients require additional agents to control their cutaneous disease. (See Workup and Treatment.)

SCLE lesions heal without scarring or atrophy, but they may result in dyspigmentation, which can be prominent. Severe systemic disease is unusual, but when it occurs, the patient may develop life-altering sequelae.



Subacute cutaneous lupus erythematosus (SCLE) occurs in genetically predisposed individuals, most often in patients with human leukocyte antigen B8 (HLA-B8), human leukocyte antigen DR3 (HLA-DR3), human leukocyte antigen DRw52 (HLA-DRw52), and human leukocyte antigen DQ1 (HLA-DQ1). A strong association exists with anti-Ro (SS-A) autoantibodies, as greater than 80% of patients with SCLE have anti-Ro (SS-A) positivity.[2] The reaction is believed to be related to ultraviolet (UV) light modulation of autoantigens, epidermal cytokines, and adhesion molecules, with resultant keratinocyte apoptosis. One study demonstrated that patients with SCLE, as well as those with discoid LE, but not those with lupus tumidus, have elevated levels of type I IFN-regulated genes in their blood. Furthermore, the levels were correlated with the patients' cutaneous disease activity severity levels as measured by the Cutaneous Lupus Area and Severity Index (CLASI).[3]

SCLE usually manifests following UV light exposure, but other triggers or inciting factors may also be involved given that not all patients have disease that follows photoexposure. Exacerbation of disease or induction of lesions is more common following UV-B exposure, but it can also occur in patients exposed to UV-A. Some patients exhibit sensitivity to only UV-A or to UV-A and UV-B.[4]

In perhaps as many as 30% of patients with SCLE, drugs may exacerbate or induce their disease.[5] Traditionally, hydrochlorothiazide has been the most frequently implicated drug; however, other antihypertensive agents, along with a list of over 100 different agents, have been reported in relation to the induction or exacerbation in individual patients.[6]

Additional implicated agents include calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs, antifungal agents (particularly terbinafine), chemotherapy agents, proton pump inhibitors, and tumor necrosis factor (TNF) antagonists.[7, 8, 9, 10, 11] In a recent population-based, matched case-control study of the incidence of SCLE cases in Sweden, the most increased odds ratios (OR) for developing SCLE from drug exposures were found with terbinafine (OR, 52.9), TNF antagonists (OR, 8.0), antiepileptics (OR, 3.4), and proton pump inhibitors (OR, 2.9).[12] Development and worsening of SCLE have also been reported with newer anti-TNF-agents, including golimumab.[13, 14] Therefore, a careful drug history should be part of the initial evaluation of patients with SCLE.[15]

Patients with a deficiency of the second component of complement (C2d) often manifest SCLE lesions as part of their SLE-like disease.



Worldwide, subacute cutaneous lupus erythematosus (SCLE) prevalence ranges from 17-48 cases per 100,000 persons, while the incidence of cutaneous lupus erythematosus (CLE) is 4.3 cases per 100,000 persons and that of SCLE specifically is 0.63 case per 100,000 persons.[16] The highest prevalence of systemic lupus erythematosus (SLE) occurs in patients aged 40-60 years. The male-to-female ratio of SLE is approximately 1:10. The male, to-female ratio of CLE is approximately 1:2-3.[17] Of patients with CLE, 10-50% have SCLE.

SCLE is more common in whites (>85%). The male-to-female ratio of SCLE is 1:4. The condition typically occurs in patients aged 15-70 years, with the mean age being approximately 43 years. It is estimated that 50% of patients with SCLE meet criteria for having SLE, and approximately 10% of SLE patients have SCLE lesions.



Subacute cutaneous lupus erythematosus (SCLE) uncomplicated by severe systemic lupus erythematosus (SLE) has a good prognosis. Some patients may manifest spontaneous remission; however, most have chronically active disease or a course punctuated by intermittent exacerbations. Exacerbation in the spring or summer is common. By definition, skin lesions heal without scarring or atrophy but may leave residual dyspigmentation.

Approximately half the patients with SCLE meet four or more of the criteria for classification as SLE[18] ; In these patients, the systemic disease is generally mild, with arthralgia and myalgia being the most common symptoms. However, in up to 10% of patients, severe systemic disease, including central nervous system involvement, vasculitis, or nephritis, is possible.[19] Individuals with the papulosquamous type of SCLE may be more likely to develop renal disease.[20]

Patients with SCLE usually have relatively minimal systemic disease. In a 2016 retrospective study assessing 85 patients with SCLE who fulfilled both the 1997 American College of Rheumatology (ACR) and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE, patients with SLCE who formally met criteria for SLE did not have more significant systemic disease when compared with SCLE-only patients. Patients with SCLE who met SLE criteria were more frequently found to have oral ulcers, a positive antinuclear antibody (ANA), positive anti-dsDNA, and low complement levels.[21]


Patient Education

Instruct patients about sun-avoidance techniques, the use of sun-protective clothing, and the appropriate use of broad-spectrum sunscreens.

Because subacute cutaneous lupus erythematosus (SCLE) is exacerbated by sunlight or other UV light exposure, advise patients to take precautions. One precaution is to discourage exposure to sunlight between the hours of 10 am and 4 pm. While this is beneficial to some patients, many are so exquisitely photosensitive that this alteration does not help. In addition, advise patients to avoid artificial light sources, such as tanning beds.

Discuss the expectations for prognosis. Patients should be educated on the systemic manifestations of systemic lupus erythematosus (SLE) and be followed regularly for these.

For patient education information, see the Arthritis Center, as well as Lupus (Systemic Lupus Erythematosus).

Contributor Information and Disclosures

Janice Lin, MD, MPH Clinical Instructor, Department of Immunology and Rheumatology, Stanford University School of Medicine

Janice Lin, MD, MPH is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Medical Dermatology Society, Rheumatologic Dermatology Society

Disclosure: Nothing to disclose.


Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: XOMA; Biogen/IDEC; Novartis; Janssen Biotech, Abbvie, CSL pharma<br/>Received honoraria from UpToDate for author/editor; Received honoraria from JAMA Dermatology for associate editor and intermittent author; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Ruth Ann Vleugels, MD, MPH Assistant Professor of Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women's Hospital; Associate Physician, Department of Immunology and Allergy, Children's Hospital Boston

Ruth Ann Vleugels, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Rheumatology, American Medical Association, Society for Investigative Dermatology, Medical Dermatology Society, Dermatology Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Lester F Libow, MD Dermatopathologist, South Texas Dermatopathology Laboratory

Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

  1. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013 Jan. 12(3):444-54. [Medline].

  2. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007 Oct. 33(1-2):85-106. [Medline].

  3. Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012 May. 166(5):971-5. [Medline]. [Full Text].

  4. Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum. 1995 Aug. 38(8):1152-6. [Medline].

  5. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012 Aug. 167(2):296-305. [Medline].

  6. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985 Jul. 103(1):49-51. [Medline].

  7. Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006 May. 54(5 Suppl):S242-3. [Medline].

  8. Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005 Oct. 52(10):3073-8. [Medline].

  9. Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. 2005 Nov. 46(4):266-9. [Medline].

  10. Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006. 212(1):59-65. [Medline].

  11. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013 Sep. 149(9):1071-5. [Medline].

  12. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012 Aug. 167(2):296-305. [Medline].

  13. Brunasso A, Aberer W, Massone C. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus. 2014. 23(2):201-3. [Medline].

  14. Wilkerson E, Hazey MA, Bahrami S, Callen JP. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol. 2012 Oct. 148(10):1186-90. [Medline].

  15. Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011 Mar. 164(3):465-72. [Medline].

  16. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar. 145 (3):249-53. [Medline].

  17. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar. 145(3):249-53. [Medline].

  18. Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. 1994 Sep. 21 (9):1665-9. [Medline].

  19. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985 Jul-Sep. 3 (3):58-68. [Medline].

  20. Callen JP, Kulick KB, Stelzer G, Fowler JF. Subacute cutaneous lupus erythematosus. Clinical, serologic, and immunogenetic studies of forty-nine patients seen in a nonreferral setting. J Am Acad Dermatol. 1986 Dec. 15(6):1227-37. [Medline].

  21. Tiao J, Feng R, Carr K, Okawa J, Werth VP. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). J Am Acad Dermatol. 2016 Feb 18. [Medline].

  22. Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997 Jul. 77 (4):305-8. [Medline].

  23. David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, Lee LA. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol. 1992 Sep. 99 (3):251-7. [Medline].

  24. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006 Sep-Oct. 24 (5):348-62. [Medline].

  25. Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016 Feb 12. [Medline].

  26. Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum. 2004 Sep. 50(9):3045-6. [Medline].

  27. Stege H, Budde MA, Grether-Beck S, Richard A, Rougier A, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Eur J Dermatol. 2002 Jul-Aug. 12(4):VII-IX. [Medline].

  28. Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan. 64(1):37-48. [Medline].

  29. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011 Nov. 147(11):1261-7. [Medline]. [Full Text].

  30. Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012 Apr. 148(4):479-84. [Medline].

  31. Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. Lupus. 2013 Aug. 22(9):932-9. [Medline].

  32. Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003 Jan. 139(1):50-4. [Medline].

  33. Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2008 Jan. 6(1):48-59. [Medline].

  34. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. 2007 Jul. 143(7):873-7. [Medline].

  35. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov. 71 (11):1833-8. [Medline].

  36. Cortés-Hernández J, Avila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012 Dec 7. 14(6):R265. [Medline]. [Full Text].

  37. Cusack C, Danby C, Fallon JC, Ho WL, Murray B, Brady J, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008 Oct. 24(5):260-7. [Medline].

  38. Klaeschen AS, Wenzel J. Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous. Expert Rev Clin Pharmacol. 2016 Jan 22. [Medline].

  39. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007. 16(6):401-9. [Medline].

  40. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 Mar. 62(3):863-8. [Medline].

  41. Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum. 1988 Aug. 31(8):1007-13. [Medline].

  42. Callen JP. Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005 Oct. 19(5):767-84. [Medline].

  43. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006 Feb. 47(1):13-27. [Medline].

  44. Huber A, Tüting T, Bauer R, Bieber T, Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol. 2006 Oct. 155(4):861-2. [Medline].

  45. Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005. 85(6):545-7. [Medline].

  46. Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005 Jul. 153(1):157-62. [Medline].

  47. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007 Jun. 156(6):1321-7. [Medline].

Early lesions of subacute cutaneous lupus erythematosus may simulate polymorphous light eruption.
Papulosquamous lesions of subacute cutaneous lupus erythematosus may simulate psoriasis.
Annular lesions of subacute cutaneous lupus erythematosus.
Tumid lupus erythematosus.
Neonatal lupus erythematosus.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.